Rabies vaccine 1 is under clinical development by Beijing Minhai Biotechnology and currently in Phase III for Rabies. According to GlobalData, Phase III drugs for Rabies have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Rabies vaccine 1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Rabies vaccine 1 overview

Vaccine candidate is under development for the prevention of rabies. The vaccine candidate is a freeze-dried/lyophilized vaccine.

Beijing Minhai Biotechnology overview

Beijing Minhai Biotechnology (Minhai), a subsidiary of Shenzhen Kangtai Biological Products Co Ltd is involved in the research, development, production, and marketing of bacteria and virus vaccine products for infectious diseases. Its product line includes Hib conjugate vaccine, DTaP-Hib vaccine, MR vaccine and 23 valent PPSV vaccine. The company’s pipeline products comprise valent PCV, HDCV rabies vaccine, sabin IPV and PENTA among others, which are in pre-clinical trial to New Drug Application (NDA). The company supplies its products through registered distributors across various countries such as Uzbekistan, the Philippines, India, Russia, and Pakistan. Minhai is headquartered in Beijing, China.

For a complete picture of Rabies vaccine 1’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.